Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer

July 26, 2017

Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Multidisciplinary team management is essential for the optimal delivery of combined modality treatment for patients with localized gastric cancer. The selection of preoperative and/or postoperative therapy should be based on the stage of the disease, the extent of lymph node dissection, and surgical margins. Improved understanding of the molecular mechanisms of gastric cancers has led to the development of novel therapeutic strategies for advanced or metastatic cancer. In patients with locally advanced or metastatic disease, the decision to offer systemic therapy should be based on the toxicity profile of each drug, patient’s performance status, comorbidities and HER-2 status. Best supportive care for the prevention and management of treatment-related adverse events is always indicated throughout the disease course. It is essential that clinicians use appropriate interventions to relieve major symptoms in order to improve the quality of life and optimize clinical outcomes.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Lilly
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.


Supporter list last updated on June 7, 2017.

Course summary
Available credit: 
  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
07/26/2017
Course expires: 
09/24/2017
Event starts: 
07/26/2017 - 1:00pm
Event ends: 
07/26/2017 - 2:00pm
Cost:
$0.00

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer

Laura H. Tang, MD, PhD
Memorial Sloan Kettering Cancer

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. Pending approval, the activity code and approval number will be posted prior to the activity date.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN will be posted prior to the activity date.

Available Credit

  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Review the current standard of care for the management of patients with localized and metastatic gastric cancer.
  • Develop an individualized treatment plan incorporating combined modality therapy for patients with locoregional gastric cancer.
  • Evaluate the role of targeted therapies for the treatment of locally advanced or metastatic gastric cancer and identify patients who would benefit from these treatment options.

Accreditation Period

Course opens: 
07/26/2017
Course expires: 
09/24/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing